

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16871

Title: Advanced pancreatic cancer - how to choose an adequate treatment option

Reviewer's code: 00055107

Reviewer's country: Spain

Science editor: Yuan Qi

Date sent for review: 2015-02-01 19:50

Date reviewed: 2015-03-28 02:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review is focused on the treatment of advanced pancreatic cancer. The author compares the efficacy and the side effects evoked by several chemotherapies published in previous clinical studies. This is a well written paper with an updated bibliography and correct English.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16871

Title: Advanced pancreatic cancer - how to choose an adequate treatment option

Reviewer's code: 03104626

Reviewer's country: 0

Science editor: Yuan Qi

Date sent for review: 2015-02-01 19:50

Date reviewed: 2015-02-11 17:48

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In this review Dr. Korkeila describes the therapeutic options for advanced pancreatic cancer. The paper is well written and describes the possible chemotherapeutic options, first and second line. However the title is misleading because reading "Advanced pancreatic cancer-how to choose and adequate treatment option" one may expect also indications for surgery. Maybe it be worthwhile to modify in "chemotherapy treatment options".

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16871

Title: Advanced pancreatic cancer - how to choose an adequate treatment option

Reviewer's code: 00052016

Reviewer's country: Japan

Science editor: Yuan Qi

Date sent for review: 2015-02-01 19:50

Date reviewed: 2015-04-06 14:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript focuses on the review of medical management of advanced pancreatic cancer. However, the content of this manuscript is superficial and it is difficult to accept this manuscript for publication in the World Journal of Gastroenterology. General 1. Authors mentioned that risk benefit balance is important for choice of chemotherapy regimen, especially FOLFIRINOX and nab-PTX/Gem. However, their explanations are superficial. Detailed patients' characteristics, for instance, primary site (head or body/tail), presence of biliary stent, status of UGT1A1 polymorphism, age, etc., should be discussed. 2. NCIC CTG PA.3 trial, comparing Gemcitabine/erlotinib to Gemcitabine monotherapy, was cited in the targeted therapy section. As mentioned in the text, median survival time was 6.24 months vs. 5.91 months, respectively. However, description of difference with only a point estimate is unfair. To compare two different treatments in terms of survival, an interval estimate or hazard ratio with 95% confidence interval should be described for better interpretation. Minor 1. "Toxicity" or "adverse event" is more suitable for describing bad events during chemotherapy than "side effect". 2. At least, published Phase 3 trial for gemcitabine refractory pancreatic cancer (Pelzer U, Eur J Cancer 2011, Oettle H, J Clin Oncol 2014) should be



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

discussed.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16871

Title: Advanced pancreatic cancer - how to choose an adequate treatment option

Reviewer's code: 00057875

Reviewer's country: United States

Science editor: Yuan Qi

Date sent for review: 2015-02-01 19:50

Date reviewed: 2015-04-02 02:34

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The review entitled "Advanced Pancreatic Cancer – How to Choose an Adequate Treatment Option" by Dr. Korkeila describes the chemoresistance of pancreatic cancer as well as various first and second-line therapeutic options available to date. The review is well-written although a bit brief. Comments: 1. "Advanced" pancreatic cancer should be defined – does this mean resectable, unresectable, metastasized? Stage? 2. The authors raise the question: "Why is pancreatic cancer so resistant to treatment?" This topic should be explored in greater depth. More information should be provided about the genetic mutations as well as other mechanisms (transport etc). In addition, innate as well as acquired chemoresistance should be addressed with respect to pancreatic cancer. 3. Finally, it would be informative and helpful to discuss future directions – how improvements can be made, what is needed etc.